Open Access<p>Multifocal ERG and Microperimetry Changes in Response to Ranibizumab Treatment of Neovascular AMD: Randomized Phase 2 Open-Label Study</p>
Author(s) -
Masumi G Asahi,
Josh Wallsh,
Spencer M Onishi,
Shari Kuroyama,
Ron P. Gallemore
Publication year - 2020
Publication title -
clinical ophthalmology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.025
H-Index - 56
eISSN - 1177-5483
pISSN - 1177-5467
DOI - 10.2147/opth.s270243
Subject(s) - microperimetry , medicine , ranibizumab , ophthalmology , pro re nata , macular degeneration , cohort , diabetic retinopathy , visual acuity , bevacizumab , diabetes mellitus , chemotherapy , endocrinology
To compare monthly versus pro re nata (PRN) ranibizumab injections in the treatment of exudative macular degeneration (AMD) while assessing the utility of microperimetry (MP) and multifocal electroretinography (mfERG) testing when monitoring response to treatment.